PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

News provided by

Oct 29, 2013, 07:31 ET

NEW YORK, Oct. 29, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01544040/PharmaPoint-Meningococcal-Vaccines---Brazil-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022". Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

GlobalData predicts that market share for private vaccine manufacturers to virtually disappear over the course of the forecast, with Brazil unleashing domestically-produced MenC conjugate vaccines that are more cost-effective for the government-funded healthcare system. These vaccines, which include a MenC conjugate vaccine and a heptavalent pediatric vaccine (DTP-Hib-HepB-IPV-MenC) are being developed and produced by government-sponsored institutions such as Bio-Manguinhos, Instituto Butantan, Fiocruz, and FUNED. Once they become widely available, these vaccines will quickly steal market share from private manufacturers because of their cost-effectiveness advantage.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Brazil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Brazil from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Brazil Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Brazil

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 16
3.3 Prognosis 17
4 Disease Management 18
4.1 Meningococcal Immunization Policy 19
4.2 Brazil 21
4.2.1 Meningococcal Immunization Recommendations and Policies 21
4.2.2 Clinical Practice 22
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitor Assessment 24
5.3 Product Profiles – Major Brands 26
5.3.1 Meningitec 26
5.3.2 Menjugate 29
5.3.3 NeisVac-C 32
6 Opportunity and Unmet Need 35
6.1 Overview 35
6.2 Unmet Needs 36
6.2.1 Unmet Need: Protection Against Serogroup B Disease 36
6.2.2 Unmet Need: A Pentavalent (MenABCWY) Vaccine 37
6.2.3 Unmet Need: More Cost-Effective Vaccines 38
6.2.4 Unmet Need: Improved Duration of Immunity in Children and Adolescents 39
6.2.5 Unmet Need: Immunogenic Infant Vaccines 40
6.2.6 Unmet Need: Improved Vaccination Coverage Rates 41
6.2.7 Unmet Need: Increased Patient Awareness and Education 42
6.3 Unmet Needs Gap Analysis 43
6.4 Opportunities 44
6.4.1 Opportunity: Broadening Serogroup Protection with New and Existing Antigen Combinations 44
6.4.2 Opportunity: Improving Immune Response Duration with Adjuvants 45
6.4.3 Opportunity: Developing More Cost-Effective Vaccines by Partnering with Manufacturers in Emerging Markets 45
7 Pipeline Assessment 46
7.1 Overview 46
7.2 Promising Vaccines in Clinical Development 47
7.3 Promising Vaccines in Early Clinical Development 48
7.3.1 MenC conjugate 49
7.3.2 Heptavalent DTP-Hib-HepB-IPV-MenC 52
8 Market Outlook 55
8.1 Brazil 55
8.1.1 Forecast 55
8.1.2 Key Events 58
8.1.3 Drivers and Barriers 59
9 Appendix 61
9.1 Bibliography 61
9.2 Abbreviations 66
9.3 Methodology 68
9.4 Forecasting Methodology 68
9.4.1 Vaccine Coverage 69
9.4.2 Vaccine Approval vs. Routine Schedule Inclusion 70
9.4.3 Vaccines Included 70
9.4.4 General Pricing Assumptions 70
9.4.5 Individual Vaccine Assumptions 71
9.5 Physicians and Specialists Included in this Study 73
9.6 About the Authors 77
9.6.1 Authors 77
9.6.2 Reviewers 77
9.6.3 Global Head of Healthcare 78
9.7 About GlobalData 79
9.8 Disclaimer 79

List of Tables

Table 1: Symptoms of Meningococcal Disease 16
Table 2: Meningococcal Immunization Recommendation Agencies by Country 19
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 20
Table 4: Leading Vaccines for Meningococcal Disease, 2012 25
Table 5: Product Profile – Meningitec 27
Table 6: Meningitec SWOT Analysis, 2012 28
Table 7: Product Profile – Menjugate 30
Table 8: Menjugate SWOT Analysis, 2012 31
Table 9: Product Profile – NeisVac-C 33
Table 10: NeisVac-C SWOT Analysis, 2012 34
Table 11: Overall Unmet Needs – Current Level of Attainment 35
Table 12: Clinical Unmet Needs – Gap Analysis, 2012 43
Table 13: Product Profile – MenC conjugate 50
Table 14: MenC conjugate SWOT Analysis, 2012 51
Table 15: Product Profile – Heptavalent DTP-Hib-HepB-IPV-MenC 52
Table 16: Heptavalent DTP-Hib-HepB-IPV-MenC SWOT Analysis, 2012 54
Table 17: Sales Forecasts ($m) for Meningococcal Vaccines in Brazil, 2012–2022 56
Table 18: Key Events Impacting Sales for Meningococcal Vaccines in Brazil, 2012–2022 58
Table 19: Brazil Meningococcal Vaccines Market – Drivers and Barriers, 2012–2022 59
Table 20: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 76